PRO-MIRTAZAPINE TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
20-10-2023
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
MIRTAZAPINE
Beschikbaar vanaf:
PRO DOC LIMITEE
ATC-code:
N06AX11
INN (Algemene Internationale Benaming):
MIRTAZAPINE
Dosering:
30MG
farmaceutische vorm:
TABLET
Samenstelling:
MIRTAZAPINE 30MG
Toedieningsweg:
ORAL
Eenheden in pakket:
15G/50G
Prescription-type:
Prescription
Therapeutisch gebied:
MISCELLANEOUS ANTIDEPRESSANTS
Product samenvatting:
Active ingredient group (AIG) number: 0143928002; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2008-07-02
Productkenmerken
PRO-MIRTAZAPINE
Page 1 of 43
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PRO-MIRTAZAPINE
Mirtazapine Tablets
15 mg, 30 mg and 45 mg
House Standard
ANTI-DEPRESSANT
Pro Doc Ltée.
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Submission Control No.: 279376
Date of Initial
Approval:
July 02,2008
Date of Revision:
October 20, 2023
PRO-MIRTAZAPINE
Page 2 of 43
RECENT MAJOR LABEL CHANGES
7. WARNINGS AND PRECAUTIONS, Skin 08/2021
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1 INDICATIONS
..........................................................................................................................
4
1.1 Pediatrics
...........................................................................................................................
4
1.2 Geriatrics
...........................................................................................................................
4
2 CONTRAINDICATIONS
............................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................................
5
4 DOSAGE AND ADMINISTRATION
............................................................................................
5
4.1 Dosing Considerations
.......................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.................................................................. 5
4.3 Administration
...................................................................................................................
6
4.4 Reconstitution
...................................................................................................................
6
4.5 Missed Dose
......................................................................................................................
6
5 OVERDOSAGE ...........
Lees het volledige document
